Mostrar registro simples

dc.contributor.authorAzúa García, Sonia Ruiz dept_BR
dc.contributor.authorMatute, Carlospt_BR
dc.contributor.authorStertz, Laurapt_BR
dc.contributor.authorMosquera, Fernandopt_BR
dc.contributor.authorPalomino, Aitorpt_BR
dc.contributor.authorDe la Rosa, Irispt_BR
dc.contributor.authorBarbeito, Sarapt_BR
dc.contributor.authorVega, Patriciapt_BR
dc.contributor.authorKapczinski, Flávio Pereirapt_BR
dc.contributor.authorGonzález-Pinto, Anapt_BR
dc.date.accessioned2015-02-12T02:15:17Zpt_BR
dc.date.issued2013pt_BR
dc.identifier.issn1471-244Xpt_BR
dc.identifier.urihttp://hdl.handle.net/10183/110036pt_BR
dc.description.abstractBackground: Cognitive impairments are seen in first psychotic episode (FEP) patients. The neurobiological underpinnings that might underlie these changes remain unknown. The aim of this study is to investigate whether Brain Derived Neurotrophic Factor (BDNF) levels are associated with cognitive impairment in FEP patients compared with healthy controls. Methods: 45 FEP patients and 45 healthy controls matched by age, gender and educational level were selected from the Basque Country area of Spain. Plasma BDNF levels were assessed in healthy controls and in patients. A battery of cognitive tests was applied to both groups, with the patients being assessed at 6 months after the acute episode and only in those with a clinical response to treatment. Results: Plasma BDNF levels were altered in patients compared with the control group. In FEP patients, we observed a positive association between BDNF levels at six months and five cognitive domains (learning ability, immediate and delayed memory, abstract thinking and processing speed) which persisted after controlling for medications prescribed, drug use, intelligence quotient (IQ) and negative symptoms. In the healthy control group, BDNF levels were not associated with cognitive test scores. Conclusion: Our results suggest that BDNF is associated with the cognitive impairment seen after a FEP. Further investigations of the role of this neurotrophin in the symptoms associated with psychosis onset are warranted.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofBMC Psychiatry. London. Vol. 13, n. 66 (2013), 27, [9] f.pt_BR
dc.rightsOpen Accessen
dc.subjectFator neurotrófico derivado do encéfalopt_BR
dc.subjectPsychotic disorderen
dc.subjectBrain-derived neurotrophic factoren
dc.subjectCogniçãopt_BR
dc.subjectAprendizagempt_BR
dc.subjectSchizophreniaen
dc.subjectCognitionen
dc.titlePlasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosispt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000875649pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples